Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 5/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277427 | 0.97 | CASP3 (0.45) | CASP3PTPN1RENCASP7MEN1 | |
| SCHEMBL30124306 | 0.95 | CASP3 (0.42) | CASP3PTPN1RENKMT2ACTSD | |
| SCHEMBL30250366 | 0.94 | CASP3 (0.42) | CASP3PTPN1 | |
| SCHEMBL30786572 | 0.93 | PTPN1 (0.43) | CASP3PTPN1 | |
| SCHEMBL30054654 | 0.89 | CASP3 (0.46) | CASP3 | |
| SCHEMBL30055074 | 0.88 | CASP3 (0.44) | CASP3PTPN1 | |
| SCHEMBL30414354 | 0.88 | PTPN1 (0.42) | CASP3PTPN1 | |
| SCHEMBL30107564 | 0.86 | CASP3 (0.54) | CASP3PTPN1 | |
| SCHEMBL29812453 | 0.85 | CASP3 (0.53) | CASP3PTPN1MEN1KMT2AATM | |
| SCHEMBL16063436 | 0.85 | PTPN1 (0.42) | PTPN1RENCTSDGRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | claimed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | claimed |
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | disclosed |
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | disclosed |
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | disclosed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023279323-A1 | METHOD FOR SYNTHESIZING GLP-1 ANALOG | 深圳翰宇药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | GCG, OGDH, ABAT | CASP3 929/4885PTPN1 4516/4885REN 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.